Breast cancer is not just one disease—it’s a collection of different types with varying molecular features and treatment responses. While many early-stage cases can be treated effectively, some forms, like triple-negative and metastatic breast cancer, remain particularly stubborn and difficult to manage.

Developed by researchers at the University of Alabama at Birmingham (UAB), this powerful new online platform is designed to help researchers and clinicians make sense of massive amounts of breast cancer data.

MammOnc-DB, a web-based proteo-genomics platform for analysis and visualization of multi-omics breast cancer data.

MammOnc-DB pulls together information from over 20,000 breast cancer samples, combining RNA sequencing, proteomics (the study of proteins), and clinical data. This allows users to explore the molecular landscape of breast cancer in one place. The platform isn’t just a data dump—it’s interactive and user-friendly, making it easier to generate hypotheses, discover new biomarkers, and even identify drug targets.

What’s especially exciting is that MammOnc-DB includes both pre- and post-treatment data. This means researchers can study how cancer cells change after therapy, uncovering clues to treatment resistance and helping design smarter combination therapies.

Whether you’re a cancer biologist, a clinician looking for insights into personalized treatment strategies, or just someone interested in the future of cancer research, MammOnc-DB represents a big step forward.

Availability – A comprehensive BCa data analysis platform called MammOnc-DB is available at: http://resource.path.uab.edu/MammOnc-Home.html